- Open Access
Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis)
© The Author(s). 2016
- Published: 6 July 2016
Among various actions taken to improve the prognosis of critical care patients, an important step is including hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) in the differential diagnosis.
HLH is an uncontrolled, self-propelling hyperinflammation. It can be initiated in a predisposed individual by various triggering factors: infection (especially viral, notably Epstein-Barr virus (EBV)), malignancy (frequently by T-cell lymphoma), or autoimmune disease. The triggering factor unleashes a positive feedback loop with extremely high concentrations of pro-inflammatory cytokines (“cytokine storm”) which leads to multiorgan failure (MOF) and death. Only timely proper diagnosis and treatment can reverse this dismal outcome.
The cause of this rare, pathologic hyperinflammation is an immune dysfunction, which in familial cases was found to result from an inherited lack of cytotoxic activity of T cytotoxic and natural killer lymphocytes, which retain the ability to release cytokines. A similar, but not fully understood, mechanism is expected in the acquired cases. Mutations in cytotoxic granule pathway genes (e.g., Perforin, UNC13D or STX11) are the cause in familial HLH . HLH was at first perceived as affecting only infants with mutations in these specific genes, but later the syndrome was also found in adolescents and adults, so the term “secondary HLH” was coined. This approach was abandoned because (regardless of age and mutation status) all HLH episodes are thought to be secondary to a triggering factor (which cannot always be identified). Nowadays, with a growing number of adult patients of whom a considerable proportion harbor a proven mutation in HLH-related genes (25 % , 14 % ), the syndrome is considered as a continuum from neonates with complete loss of cytotoxic function, through adolescents to elderly adults with mutations only partially affecting the cytotoxic activity or patients without any characteristic mutation but with symptomatic HLH.
In most patients, in the absence of genetic traits, diagnosis of HLH is based on fulfillment of five out of eight HLH 2004  criteria: 1) persistent fever; 2) splenomegaly; 3) bicytopenia (hemoglobin <9 g/dl, neutrophils <1.0 × 109/l, platelets <100 × 109/l); 4) hypofibrinogenemia (<150 mg/dl) and/ or hypertriglyceridemia (>265 mg/dl); 5) hyperferritinemia (>500 ng/ml); 6) hemophagocytosis; 7) low natural killer cell activity; and 8) high concentration of sCD25 (soluble receptor for interleukin 2).
Hemophagocytosis occurs when activated macrophages phagocytose other blood or bone marrow cells. Despite the name of the syndrome, hemophagocytosis is neither necessary nor sufficient to diagnose HLH—it is only one of the criteria. It is not an essential part of the HLH pathomechanism, but rather develops in a more advanced stage of the process . Therefore, it can be absent in patients with HLH, and it is also not pathognomonic for this syndrome. Hemophagocytosis is a frequent finding, especially in intensive care—it was observed in 64 % of the ICU patients with sepsis and thrombocytopenia  (32/50) and in 65 % deceased ICU patients  (69/107). Diagnosis of HLH is possible without bone marrow aspirate/biopsy; however, this procedure should be performed to search for underlying malignancy. Neoplasms are among the most important HLH triggers in adults and are associated with a poor prognosis .
The most important parameter, besides cytopenias, characteristic for HLH is hyperferritinemia. The specific (especially for ICU patients) values are much higher than the HLH 2004 criterion and exceed 2000–3000 ng/ml, reaching high specificity (but low sensitivity) above 10,000 ng/ml. All patients with such high ferritin values should have other HLH criteria assessed. Indications for ferritin testing are cytopenias and/or splenomegaly in a febrile patient whose clinical status and laboratory values are worsening despite standard treatment with anti-infectious therapy.
Although treatment of the trigger is important (if it is possible at all), this is usually not sufficient to suppress the high cytokine levels. Treatment modalities include immunosuppressive/immunomodulatory agents such as steroids, intravenous immunoglobulins, cyclosporine A, removal of the cytokines by plasmapheresis, and, in severe cases, etoposide . A delay in etoposide treatment was proven to have a negative impact on prognosis in EBV-associated HLH . Without immune suppression, and despite all possible efforts of intensive care, HLH is often fatal.
Raising the awareness of HLH—a life-threatening, heavily underdiagnosed syndrome—is of paramount importance, especially since the tests for preliminary diagnosis (ferritin concentration) and treatment (etoposide, steroids, cyclosporine A) are relatively inexpensive and widely available.
EBV, Epstein-Barr virus; HLH, hemophagocytic lymphohistiocytosis; ICU, intensive care unit; MOF, multiorgan failure
Publication was supported by statutory funds of the Department of Hematology, Oncology and Internal Diseases—Medical University of Warsaw, Poland.
RM wrote the manuscript. GJ and WWJ contributed intellectual input and reviewed the manuscript. All authors contributed to all subsequent critical revisions of the manuscript and have read and approved the final manuscript.
RM and GJ are members of the “HLH in Adults Working Group” of the Histiocyte Society. RM and WWJ conduct the National Registry for adult HLH patients in Poland. GJ is the most renowned specialist in HLH, especially in children. WWJ, as the National Consultant in Hematology in Poland, has greatly contributed to the HLH awareness by publications, lectures and most of all by treating adult HLH patients as early as the year 2000.
The authors declare that they have no competing interests.
Consent for publication
All authors have read and approved the manuscript and its contents and agree with its submission to Critical Care.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Henter J-I et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.View ArticlePubMedGoogle Scholar
- Cetica V et al. Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016;137:188–96. e4.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang K et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118:5794–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118:4041–52.View ArticlePubMedPubMed CentralGoogle Scholar
- François B et al. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114–20.View ArticlePubMedGoogle Scholar
- Strauss R et al. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients—a postmortem clinicopathologic analysis. Crit Care Med. 2004;32:1316–21.View ArticlePubMedGoogle Scholar
- La Rosée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology Am Soc Hematol Educ Program. 2015;2015:190–6.PubMedGoogle Scholar
- Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013;2013:605–11.PubMedGoogle Scholar
- Imashuku S et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19:2665–73.PubMedGoogle Scholar